Program
CVL006
A development code. Also written as “CVL006 in combination with 9MW2821”, “CVL006 combined with pemetrexed and carboplatin” and “CVL006 in combination with SKB264”.
Its studies are led by Convalife (Shanghai).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Convalife (Shanghai) | 33 open or running | phase 2since Aug 22, 2025 | Sep 20, 2024 | May 20, 2028phase 1 · NCT06621615 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06621615 · 120 planned
- Aug 22, 2025Phase 2 study in Advanced Solid TumorNCT07157956 · 318 planned · China
- May 6, 2026Phase 2 study in Advanced Solid TumorNCT07615660 · 108 planned
Ahead
- May 20, 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06621615
- Aug 12, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07157956
- Apr 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07615660
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07615660Advanced Solid Tumor | 2 | Not yet recruiting | Apr 30, 2029 | 108 |
| NCT07157956Advanced Solid Tumor · China | 2 | Not yet recruiting | Aug 12, 2028 | 318 |
| NCT06621615Advanced Solid Tumor | 1 | Not yet recruiting | May 20, 2028 | 120 |
How it is read
Names in the registry
- “CVL006 in combination with 9MW2821”, 2 entries
- “CVL006 combined with pemetrexed and carboplatin”, 1 entry
- “CVL006 in combination with SKB264”, 1 entry
- “CVL006 in combination with DS-8201”, 1 entry
- “CVL006 in combination with Enfortumab Vedotin”, 1 entry
Codes read as this program: CVL006.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.